<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244114</url>
  </required_header>
  <id_info>
    <org_study_id>3090A1-900</org_study_id>
    <secondary_id>B1821003; 3090A-101795</secondary_id>
    <nct_id>NCT00244114</nct_id>
  </id_info>
  <brief_title>Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients</brief_title>
  <official_title>In Vitro Evaluation Of Allergic Reactions In Hemophilia B Subjects Who Have Exhibited A Systemic Allergic Response After Exposure To BeneFIX (Nonacog Alfa; Recombinant Factor IX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the finding that anaphylactic reactions to Benefix (&quot;FIX&quot;) are associated with a
      specific IgE, a Basophil histamine release assay was selected to evaluate and demonstrate
      subject sensitization to FIX.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Descriptive presentation of the results of the Basophil histamine release assay for both study and control groups</measure>
    <time_frame>within 36 months after allergic reaction</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect and evaluate adverse events that occur from the time the subject signs the informed consent form to 15 days following the study visit will be collected</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any serious adverse events and/or adverse events of special interest occurring outside of the predefined study reporting period noted to be possibly, probably or definitely related to treatment with BeneFIX will be reported.</measure>
    <time_frame>15 days following study blood draw</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>blood draw</intervention_name>
    <description>Single blood sample collected to perform histamine release assay.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Single blood sample collected to perform histamine release assay.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Study Group:

          -  Written informed consent or assent, as applicable.

          -  Subjects with moderate to severe Hemophilia B (FIX:C &lt;5%), who have reported class II
             or class III allergic manifestations within 24 hours of a BeneFIX infusion.

        Control Group:

          -  Written informed consent or assent, as applicable.

          -  Subjects with moderate to severe Hemophilia B (FIX:C &lt;5%)

        Exclusion Criteria:

        Study group:

          -  Subjects who had no reaction when rechallenged with BeneFIX, in the absence of
             prophylactic immunomodulating therapy.

          -  Subjects whose most recent allergic manifestations with BeneFIX occurred &gt;36 months
             prior to providing written informed consent for this study.

          -  Subjects who have taken antihistamine, steroidal, or other immunosuppressive therapy
             within 72 hours of the scheduled visit for this study.

          -  Subjects with immune disorders.

          -  Subjects unable to comply with a minimum 5-day FIX washout requirement.

        Control group:

          -  Subjects with documented evidence of prior allergic reaction to any FIX product.

          -  Subjects with documented evidence of prior or current FIX inhibitor (BU &gt;0.6).

          -  Subjects have taken antihistamine, steroidal, or other immunosuppressive therapy
             within 72 hours of the scheduled study blood draw.

          -  Subjects with immune disorder.

          -  Subjects unable to comply with a minimum 5-day FIX washout requirement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3090A1-900&amp;StudyName=Study%20Evaluating%20Allergic%20Reactions%20To%20Benefix%20In%20Hemophilia%20B%20Patients</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2005</study_first_submitted>
  <study_first_submitted_qc>October 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2005</study_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia B</keyword>
  <keyword>Allergic Reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

